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Antagonistic and reciprocal interactions are known to
exist between adenosine and dopamine receptors in the
striatum. In the present study, double immunofluores-
cence experiments with confocal laser microscopy
showed a high degree of colocalization of adenosine A2A
receptors (A2AR) and dopamine D2 receptors (D2R) in
cell membranes of SH-SY5Y human neuroblastoma cells
stably transfected with human D2R and in cultured stri-
atal cells. A2AR/D2R heteromeric complexes were dem-
onstrated in coimmunoprecipitation experiments in
membrane preparations from D2R-transfected SH-SY5Y
cells and from mouse fibroblast Ltk cells stably trans-
fected with human D2R (long form) and transiently co-
transfected with the A2AR double-tagged with hemag-
glutinin. Long term exposure to A2AR and D2R agonists
in D2R-cotransfected SH-SY5Y cells resulted in coaggre-
gation, cointernalization and codesensitization of A2AR
and D2R. These results give a molecular basis for aden-
osine-dopamine antagonism at the membrane level and
have implications for treatment of Parkinson’s disease
and schizophrenia, in which D2R are involved.
Adenosine and dopamine signaling exert opposite effects in
the basal ganglia, a brain region involved in sensory-motor
integration. Thus, adenosine agonists induce motor depression
and adenosine antagonists, such as caffeine, produce motor
activation (1). These opposite effects result from specific antag-
onistic interactions between subtypes of adenosine and dopam-
ine receptors in the striatum, the main input structure of the
basal ganglia. In fact, striatal dopamine receptors and, to some
extent, adenosine receptors are segregated in the two main
populations of -aminobutyric acid (GABA) efferent neurons.
Striopallidal neurons express dopamine receptors predomi-
nantly of the D2 subtype (D2R)
1 and the highest density of
adenosine A2A receptors (A2AR) in the brain (2, 3). In the rat,
the strionigro-strioentopeduncular neurons contain dopamine
receptors predominantly of the D1 subtype (D1R) and express
exclusively adenosine receptors of the A1 subtype (A1R) (2–4).
Experimental evidence supports the existence of antagonistic
A2AR/D2R and A1R/D1R interactions, respectively, in the
GABA striopallidal and strionigro-strioentopeduncular neu-
rons (1, 5). Taken together, these data suggested proximity
between receptors, which could allow them to form heteromeric
complexes (directly or indirectly by means of adaptor proteins).
In fact, A1R and D1R were found to form heteromeric complexes
(6). Although antagonistic A2AR/D2R interactions have been
reported to play an important role in basal ganglia function, it
is still not known whether the formation of heteromeric A2AR/
D2R complexes is also involved. In the present work, the exist-
ence of selective intramembrane interactions between A2AR
and D2R in neuronal cells is demonstrated, including formation
of heteromeric A2AR/D2R complexes and their potential in-
volvement in cross-desensitization mechanisms via agonist-
induced coaggregation and cointernalization of A2AR and D2R.
These results have clinical implications for Parkinson’s disease
and other basal ganglia disorders where dopamine D2R are the
target for therapy (1, 5).
EXPERIMENTAL PROCEDURES
Cell Cultures—Maintenance of SH-SY5Y cells (parental and D2R-
transfected cells) as well as the pharmacological characterization and
maintenance of D2R- and D1R-transfected mouse fibroblast Ltk
 cells
are described in detail elsewhere (7–9). For primary cultures, striata
were removed from 16-day-old Sprague-Dawley rat embryos (B&K Uni-
versal) in Ca2/Mg2-free PBS supplemented with 20 units/ml penicil-
lin and 20 g/ml streptomycin (Invitrogen). The tissue fragments were
pooled and mechanically dissociated in SFM Neurobasal serum-free
medium (Invitrogen), supplemented with B27 (Invitrogen), glutamine
(2 mM; Invitrogen), penicillin/streptomycin (20 units/ml/20 g/ml; In-
vitrogen), and -mercaptoethanol (25 M) (Invitrogen). Cells were col-
lected by centrifugation at 100  g for 5 min and resuspended in fresh
medium. The resulting single-cell suspension was seeded on 24-well
plates coated with gelatin (Sigma) and poly-L-lysine (Sigma), and cells
were grown at 37 °C in saturation humidity with 5% CO2.
Immunolabeling Experiments—Neuroblastoma cells were grown on
glass coverslips coated with poly-L-lysine (Sigma) and exposed to vari-
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ous amounts of CGS21680 (RBI) and/or quinpirole (RBI) in serum-free
medium for 3 h at 37 °C. They were then rinsed with PBS, fixed in 4%
paraformaldehyde and 0.06 M sucrose for 15 min, and washed with PBS
containing 20 mM glycine. Cells were subsequently treated with PBS,
containing 20 mM glycine, and 1% bovine serum albumin for 30 min at
room temperature. Double immunostaining was performed with fluo-
rescein-conjugated anti-A2AR antibodies (VC21-FITC, 40 g/ml) (10)
and rhodamine-conjugated anti-D2R antibodies (D2-246-316, 30 g/ml)
(11) for 1 h at 37 °C. Antipeptide antisera against A2AR were raised in
New Zealand White rabbits and characterized as described elsewhere
(12). The specific peptide corresponds to the second extracellular loop of
the receptor. Anti-A2AR antibodies (VC21) were purified by affinity
chromatography using the specific peptide coupled to activated thiol-
Sepharose 4B. The coverslips were rinsed for 40 min in the same buffer
and mounted with medium suitable for immunofluorescence (ICN).
Internalization assays were made as reported elsewhere (12) with some
modifications. Cells were incubated in serum-free medium (4 °C, 2 h)
with VC21-FITC and rhodamine-conjugated D2-246-316 in the absence
(control) or presence of 200 nM CGS 21680 and/or 50 M quinpirole.
Cells were washed with the same medium (without ligands in the
control experiments), and internalization of labeled receptors was in-
duced by incubation at 37 °C for 3 h. Cells were fixed and processed as
described above. Striatal cultures were exposed to various amounts of
CGS21680 and/or quinpirole in the same medium for 6 h at 37 °C. They
were then rinsed with PBS, fixed with 4% paraformaldehyde containing
2% picric acid for 1 h, and washed with PBS supplemented with 20 mM
glycine. Double or single immunostaining was performed with fluores-
cein-conjugated anti-A2AR antibodies and rhodamine-conjugated anti-
D2R (D2-246-316) antibodies or fluorescein-conjugated anti-A1R anti-
bodies (PC21-FITC) (13) for 1 h at 37 °C. Microscopic observations were
made in Leica TCS 4D (Leica Lasertechnik) confocal scanning laser
equipment adapted to an inverted Leitz DMIRBE microscope. Image
analysis was performed with a KS 400 image analyzer (Zeiss). After
acquisition of the superimposed images (yellow color) of the A2AR/D2R
IR, the area of the cell nucleus was interactively discarded. Densito-
metric evaluation was performed on this new image. The median values
of the histograms representing the intensity of A2R/D2R IR in areas
with coaggregates (interactively encircled) and in areas with no or few
aggregates (interactively encircled) were taken as representative val-
FIG. 1. A, double immunofluorescence staining and confocal images of
SH-SY5Y neuroblastoma cells stably transfected with the cDNA encod-
ing for human D2R (long form). Cells were processed for immuno-
staining using fluorescein (green)-conjugated rabbit anti-A2AR antibod-
ies and rhodamine (red)-conjugated rabbit anti-D2R antibodies and
analyzed by confocal microscopy. Superimposition of images (panels
c–h) reveals the colocalization of A2AR and D2R in yellow. Panels a–c
show A2AR immunoreactivity (a), D2R immunoreactivity (b), and A2AR/
D2R colocalization (c) in nontreated cells (no agonist preincubation).
Panels d–g show the effects of 3 h of treatment at 37 °C with CGS-21680
(100 nM) alone (d), quinpirole (10 M) alone (e), CGS-21680 (100 nM) and
quinpirole (10 M) (f), or CGS-21680 (200 nM) and quinpirole (50 M) (g).
Cells were processed for immunostaining after agonist preincubation.
Representative images from four independent experiments/treatment
are shown; scale bars, 10 m. B, semiquantitation of images from
panels c–g in A. The area (light gray) where diffuse IR (no or few
coaggregates) and the area (dark gray) where several coaggregates
could be detected were interactively selected. The median intensity
values (left y axis) for these two types of areas, obtained in the four
experimental conditions mentioned above (c–g), are given. The Gini’s
indexes (right y axis) for the four experimental conditions (c–g) are
given. It should be noticed that the Gini’s index is low (rather even
distribution of the IR intensity among pixels) for nontreated cells (c),
whereas the Gini’s index is high (rather uneven distribution of the IR
intensity among pixels) for co-treatment with CGS-21680 (200 nM) plus
quinpirole (50 M) (g).
FIG. 2. Agonist-induced internalization of A2AR and D2R in
SH-SY5Y neuroblastoma cells stably transfected with the cDNA
encoding for human D2R (long form). Cells were processed for
immunostaining using fluorescein (green)-conjugated rabbit anti-A2AR
antibodies and rhodamine (red)-conjugated rabbit anti-D2R antibodies
and analyzed by confocal microscopy. Superimposition of images re-
veals the colocalization of A2AR and D2R (yellow). Cells were first
incubated with anti-A2AR and anti-D2R antibodies for 2 h at 4 °C in the
presence (b–d) or absence (a) of the agonists. The cells were then placed
at 37 °C for 3 h allowing ligand-induced internalization of previously
labeled receptors. Panel a shows the weak diffuse immunoreactivity of
nonpretreated control cells (compare with Fig. 1, panels c). Panels b–d
show the effects of 3 h of treatment at 37 °C with CGS-21680 (200 nM)
alone (b), quinpirole (50 M) alone (c), or CGS-21680 (200 nM) and
quinpirole (50 M) (d). Representative images from four independent
experiments/treatment are shown; scale bars, 10 m.
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ues in their respective areas. A quantitative evaluation of the degree of
unevenness of the A2AR/D2R receptor codistribution was obtained by
calculating the Gini’s index (14, 15), which here measures the distribu-
tion of the IR intensity, pixel by pixel, in the sampled area. The Gini’s
index ranges from 0 (even distribution, i.e. the IR intensity is equally
distributed among pixels) to 1 (maximal concentration, i.e. the IR in-
tensity is concentrated in one single pixel) (14).
Coimmunoprecipitation Experiments—SH-SY5Y neuroblastoma cell
membranes were obtained by disrupting the cells with a Polytron ho-
mogenizer (Kinematica, PTA 20TS rotor, setting 4; Brinkmann) for
three 5-s periods in 50 mM Tris-HCl, pH 7.4. Membranes were sepa-
rated by centrifugation at 105,000  g for 45 min at 4 °C. They were
then solubilized in ice-cold lysis buffer (PBS, pH 7.4, Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS) for 1 h on ice and then centrifuged at
80,000  g for 90 min. The supernatant was immunoprecipitated as
previously described (6) using anti-A2AR antibodies (VC21) or an irrel-
evant IgG covalently coupled to protein A-Sepharose. Immunoprecipi-
tates were resolved by SDS-PAGE, and Western blots were performed
with anti-A2AR, anti-A1R (PC11), or anti-D2R antibodies (for details, see
Ref. 6).
D2R- and D1R transfected mouse fibroblast Ltk
 cells were tran-
siently transfected with A2AR cDNA double-tagged with hemagglutinin
(HA-A2AR-HA) (16) by calcium phosphate precipitation (8, 9). Immuno-
precipitation of HA-A2AR-HA was performed with anti-HA antibodies
(Babco) covalently coupled to protein G-Sepharose. Immunoprecipita-
tion and immunoblotting were done following standard protocols (6).
Immunoblots were developed with ECL Western blot detection system.
cAMP Accumulation Experiments—Neuroblastoma or striatal cells
were incubated with [3H]adenine (24 Ci/mmol; Amersham Biosciences;
1 Ci/well) for 2 h at 37 °C in serum-free medium. They were subse-
quently washed with PBS and incubated for 10 min at 37 °C in PBS
containing 100 M phosphodiesterase inhibitor RO-20-1724 (Calbio-
chem). Various concentrations of forskolin, CGS 21680, and/or quinpi-
role were then added and the cells placed at 37 °C for an additional 10
min. The incubation solution was then discarded and replaced by ice-
cold 0.3 M perchloric acid containing [14C]cAMP (51.3 mCi/mmol;
PerkinElmer Life Sciences) as an internal standard. After sonication
and centrifugation (8,000  g for 5 min), [3H]cAMP present in the
supernatant was identified by sequential chromatography (17). Forma-
tion of cAMP was expressed as the percentage of conversion of total
[3H]ATP into [3H]cAMP. For statistical analysis, one-way ANOVA
(followed by post hoc Scheffe’s multiple comparison test) and Mann-
Whitney’s U test were used.
RESULTS
Colocalization of A2AR and D2R in Nontreated SH-SY5Y
Neuroblastoma Cells: Immunolabeling Experiments—A2AR/
D2R interactions were first studied in a previously character-
ized human neuroblastoma cell line (SH-SY5Y) stably trans-
fected with human D2R (long form) (about 1100 fmol/mg of
protein) (7). This cell line constitutively expresses functional
A2AR (about 200 fmol/mg of protein), the activation of which
decreases the affinity of the transfected D2R for dopamine and
counteracts D2R-mediated intracellular [Ca
2
i] response (7).
Double immunofluorescence experiments including image
FIG. 3. Immunostaining of parental SH-SY5Y neuroblastoma
cells. Untransfected SH-SY5Y cells were processed for immunostaining
using fluorescein (green)-conjugated rabbit anti-A2AR antibodies after
exposure to medium in the absence (a) or presence (b) of 100 M
quinpirole (3 h, 37 °C). Representative images from three independent
experiments are shown; scale bar, 10 m.
FIG. 4. cAMP accumulation experiments in SH-SY5Y neuro-
blastoma cells stably transfected with D2R (long form). Results
represent means  S.E. and are expressed as percentage of conversion
of total [3H]ATP to [3H]cAMP (n  6–8). A, effects of 10 M forskolin
(F), 1 M CGS 21680 (CGS), and 1 M quinpirole (Q), alone or in
combination, without agonist preincubation. Quinpirole significantly
decreased forskolin- and CGS-induced cAMP accumulation. **, p 0.01
compared with control (C);, p 0.01 compared with forskolin; , p
0.01 compared with CGS; one-way ANOVA and post hoc Scheffe’s mul-
tiple comparison test. B, effects of 10 M forskolin (F), 1 M CGS 21680
(CGS), and 1 M quinpirole (Q), alone or in combination, after preincu-
bation for 3 h with either 200 nM CGS 21680 or 50 M quinpirole.
Preincubating the cells with either agonist counteracted CGS 21680-
induced cAMP accumulation. ** and *, p  0.01 and p  0.05, respec-
tively, compared with control (C); , p  0.05 compared with forskolin;
one-way ANOVA and post hoc Scheffe’s multiple comparison test. C,
effects of 10 M forskolin in the absence (F) and presence of 1 M
quinpirole (F/Q) with and without preincubation for 3 h with 200 nM
CGS 21680 and 50 M quinpirole. The counteractive effect of quinpirole
on forskolin-induced cAMP accumulation was significantly lower after
simultaneous preincubation with A2AR and D2R agonists (17.1%/11.4%,
in median/interquartile range; n  7) than without preincubation
(40.7%/5.8%, in median/interquartile range; n  7) (p  0.01; Mann-
Whitney U test).
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analysis were performed in nonpermeabilized cells, using flu-
orescein-conjugated anti-A2AR antibodies (green color) and rho-
damine-conjugated anti-D2R antibodies (red color). As seen in
Fig. 1A (panels a and b), there is a clear spatial predominance
of D2R versus A2AR immunoreactivity, which is in agreement
with the higher D2R density found in previous binding exper-
iments (7). Confocal analysis revealed substantial colocaliza-
tion of both receptors at the membrane level (yellow color in
Fig. 1A, panel c), which indicates that in the absence of exog-
enous agonists the lateral distance between the two receptor
proteins is less than 0.1 m. A semi-quantitative analysis of
the distribution of the yellow was done by evaluating the in-
tensity of the color (which directly reflects the amount of coex-
isting receptors) and calculating the Gini’s index or GI (a meas-
ure of unevenness, which evaluates the proportion of
coaggregates in the sampled area). These calculations were
completed on the whole cell body membrane, as well as on the
areas of the cell body membrane containing coaggregates and on
the parts with few or no coaggregates (Fig. 1B). In nontreated
cells (Fig. 1A, panel c), high amounts of coexisting receptors were
found both in the cell body membrane with coaggregates and in
the cell body membrane displaying a more diffuse distribution of
A2AR/D2R IR. The GI value of these cells was 0.10, indicating a
rather even distribution of the colocated A2AR/D2R IR and few
coaggregates of the two receptors (Fig. 1B).
Coaggregation of A2AR and D2R in CGS 21680- or Quinpi-
role-treated SH-SY5Y Cells: Immunolabeling Experiments—
Substantial modifications of A2AR and D2R distribution were
obtained when the cells were treated with the A2AR agonist
CGS 21680 or the D2R agonist quinpirole. Hence, 3 h of treat-
ment with either CGS 21680 (100 nM, Fig. 1A, panel d) or
quinpirole (10 M, Fig. 1A, panel e) induced an aggregation of
both A2AR and D2R. Similar effects were also observed with
shorter incubation times at higher agonist concentrations (data
not shown). Thus, 3 h of incubation at these concentrations give
a maximal effect. The computer-assisted analysis of the confo-
cal images showed an increase in unevenness of the yellow
distribution (GI for the entire cell body membrane was 0.23 for
CGS 21680- and 0.20 for quinpirole-treated cells). Further-
more, the yellow intensity value was still high for the cell body
membrane with A2AR/D2R coaggregates but very low for the
cell body membrane with diffusely distributed A2AR/D2R IR
(Fig. 1B). Altogether, this analysis indicates the presence on
the cell body membrane of an increased proportion of A2AR/D2R
coaggregates.
Cointernalization of A2AR and D2R in CGS 21680- or Quin-
pirole-treated SH-SY5Y Cells: Immunolabeling Experiments—
Cotreatment with CGS 21680 (100 nM) and quinpirole (10 M)
markedly decreased the yellow intensity values of the cell body
membrane associated with coaggregates and diffusely distrib-
uted A2AR/D2R IR as compared with untreated cells (Fig. 1, A
(panel f) and B). This indicates that cotreatment with CGS
21680 (100 nM) and quinpirole (10 M) induces coaggregation
followed by cointernalization of A2AR and D2R. A stronger
reduction in D2R IR (red) was, however, obtained with higher
concentrations of quinpirole (50 M) and CGS 21680 (200 nM)
(Fig. 1A, panel g). At these concentrations of the agonists, the
Gini’s index was high (0.30) reflecting an uneven distribution of
A2AR/D2R IR. In addition, the values for the yellow intensity in
the cell body membrane with A2AR/D2R coaggregates and the
cell body membrane with diffusely distributed A2AR/D2R IR
were, respectively, low and very low (Fig. 1B). This suggests
that a cotreatment of the cells with high doses of the agonists
potentiates both coaggregation and cointernalization of A2AR
and D2R. Ligand-induced cointernalization was confirmed in
experiments where cells were first labeled with anti-A2AR and
anti-D2R antibodies for 2 h at 4 °C in the absence (Fig. 2, panel
a) or in the presence of CGS21680 (200 nM) and/or quinpirole
(50 M) (Fig. 2, panels b–d). Subsequently, the ligand-induced
internalization of labeled receptors was allowed to occur by
incubating the cells for 3 h at 37 °C. Confocal analysis revealed
colocalized A2AR/D2R aggregates inside the cell after pretreat-
ment with either CGS 21680 (200 nM) or quinpirole (50 M)
(Fig. 2, panels b and c), which became more pronounced after
pretreatment with both compounds (Fig. 2, panel d).
Absence of Quinpirole-induced Aggregation of A2AR in Paren-
tal SH-SY5Y Cells: Immunolabeling Experiments—The in-
volvement of D2R in quinpirole-mediated effects was assessed
using parental neuroblastoma SH-SY5Y cells, which express
very low levels of D2R (7). Hence, quinpirole at 100 M for 3 h
did not induce any modification of A2AR immunolabeling
pattern (Fig. 3).
Codesensitization of A2AR and D2R in CGS 21680- and Quin-
pirole-treated SH-SY5Y Cells: cAMP Accumulation Experi-
ments—Under basal conditions 1 M CGS 21680 significantly
increased cAMP accumulation in SH-SY5Y neuroblastoma
cells (Fig. 4A). Quinpirole (1 M) did not modify cAMP levels
but significantly counteracted both forskolin (10 M)-induced
and CGS 21680-induced increases in cAMP accumulation (Fig.
4A). These results confirm the existence of functional and in-
FIG. 5. Coimmunoprecipitation of A2AR and D2R from membrane preparations of SH-SY5Y neuroblastoma cells stably transfected
with D2R (long form). Immunoprecipitation with anti-A2AR antibodies was followed by Western blotting with antibodies against A2AR (left),
against D2R (middle), or against A1R (right). For positive control an aliquot of cell membrane extracts was used.
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teracting A2AR and D2R in D2R-transfected neuroblastoma
cells (7). After 3 h of incubation with either 200 nM CGS 21680
or 50 M quinpirole (and subsequent withdrawal of the ago-
nists, see “Experimental Procedures”), CGS 21680 was no lon-
ger able to significantly increase cAMP levels (Fig. 4B). This
demonstrates the existence of both homologous and D2R-medi-
ated heterologous desensitization of A2AR. Instead, the inhibi-
tory effect of quinpirole on forskolin-induced elevation of cAMP
levels was about the same (40–50% inhibition) under basal
conditions and after a 3-h incubation with the A2AR or the D2R
agonist (Fig. 4, A and B). Thus, as already described, A2AR
clearly desensitized after A2AR agonist incubation (18, 19) and
D2R (long form) showed resistance to D2R agonist-induced de-
sensitization (20). However, after 3 h of incubation with both
quinpirole (50 M) and CGS 21680 (200 nM), quinpirole (1 M)
inhibited forskolin-induced cAMP accumulation by only 17.1%/
11.4% (median/interquartile range) (Fig. 4C). This effect, when
compared with the effect of quinpirole on untreated cells, was
significantly different (Mann-Whitney U test: p 0.01). Hence,
quinpirole was found to inhibit forskolin-induced cAMP accu-
mulation by 40.7%/5.8% (median/interquartile range) (Fig. 4C).
Therefore, costimulation of A2AR and D2R accelerates D2R
desensitization, likely by causing increased D2R internaliza-
tion (see above).
Coimmunoprecipitation of A2AR and D2R in Membrane Prep-
arations from SH-SY5Y Neuroblastoma Cells and Ltk Fibro-
blast Cells—The possible existence of A2AR/D2R heteromeric
complexes was then analyzed by coimmunoprecipitation per-
formed on membrane preparation of D2R-transfected SH-SY5Y
neuroblastoma cells. Immunoprecipitation with anti-A2AR an-
tibodies followed by Western blotting with anti-D2R antibodies
revealed three bands of 43, 47, and 63 kDa (Fig. 5), correspond-
ing to different glycosylated states of the D2R (21). The same
three bands were also obtained in control lysate preparations
(Fig. 5). On the other hand, immunoprecipitation with anti-
A2AR antibodies followed by Western blotting with anti-A1R
did not reveal any band corresponding to A1R, indicating the
absence of A2AR-A1R co-immunoprecipitation (Fig. 5). A West-
ern blotting performed with control lysate preparations showed
a band of 40 kDa, which corresponds to the A1R (Fig. 5).
A2AR/D2R interactions were also examined in mouse fibroblast
Ltk cells stably transfected with the human D2R (long form)
or human D1R (8, 9). These two cell lines express a similar
density of transfected dopamine receptors (2.8 pmol/mg protein
of D2R in the D2R-Ltk
 cell line and 4.2 pmol/mg protein of the
D1R in the D1R-Ltk cell line (Refs. 8 and 9)). Both cell lines
were transiently transfected with either dog A2AR cDNA dou-
ble-tagged with hemagglutinin (HA-A2AR-HA) or an irrelevant
plasmid. Antibodies against the hemagglutinin tag (anti-HA)
were able to precipitate a band of65 kDa detected in Western
blot with the anti-D2R antibodies but only from cells that
express both D2R and HA-A2AR-HA (Fig. 6). This band corre-
sponds to the highly glycosylated state of D2R (21). As a posi-
tive control, we showed that this band could also be obtained
from lysates of D2R-transfected Ltk
 cells, thus being inde-
pendent of the presence of HA-A2AR-HA. Antibodies against
anti-HA failed to coimmunoprecipitate D1R in cells expressing
D1R/HA-A2AR antibodies, assessing for the specificity of the
A2AR/D2R coimmunoprecipitation (Fig. 6). These results dem-
onstrate for the first time that A2AR and D2R assemble into
heteromeric complexes in two different cell lines that coexpress
both receptors and that these complexes exist in the absence of
exogenous agonists.
Colocalization and Coaggregation of A2AR and D2R in Cul-
tured Striatal Neurons: Immunolabeling Experiments—A2AR/
D2R interactions were also studied in neuronal primary cul-
tures of rat striatum. Cells were grown for 2 weeks and
immunostained for A2AR and D2R (see above). Immunolabeling
of A1R on nonpermeabilized cells was also performed. Most
neurons exhibited A2AR and D2R IR in the soma and in the
dendrites, however, with predominance of D2R to A2AR IR in
the dendrites (Fig. 7A). As for neuroblastoma cells, confocal
analysis revealed a high degree of A2AR/D2R colocalization in
the absence of exposure to exogenous agonists (Fig. 7A). Treat-
ment (6 h) with either the A2AR agonist CGS 21680 (100 nM) or
the D2R agonist quinpirole (10 M) induced aggregation of both
A2AR and D2R (Fig. 7A) and reduction in IR intensity. How-
ever, no synergism was observed when cells were cotreated
with CGS 21680 (100 nM) and quinpirole (10 M) for the same
time (Fig. 7A). To assess the specificity of A2AR/D2R interac-
tions, cells were incubated with 10 M quinpirole for 6 h and
immunostained with anti-A1R antibodies. No change in the
pattern of distribution of A1R present in the soma and den-
drites was observed (Fig. 7B). In addition and instead of A2AR/
D2R, no aggregates were seen, which confirms the specificity of
A2AR/D2R interactions. Cointernalization experiments analo-
gous to those described in Fig. 2 could not be performed in
cultured striatal cells, which did not tolerate the temperature
conditions of the experimental internalization protocol (cells
changed morphology and fell off the coverslip).
Interaction between A2AR and D2R in Cultured Striatal Neu-
rons: cAMP Accumulation Experiments—Both basal and fors-
kolin-induced cAMP accumulation were about 10 times higher
than in neuroblastoma cells (Fig. 8A). This could explain why,
unlike what was observed in neuroblastoma cells, CGS 21680
(1 M) did not induce any significant increase in cAMP accu-
mulation compared with basal values (Fig. 8A). As for neuro-
blastoma cells, quinpirole (1 M) did not modify cAMP levels
FIG. 6. Coimmunoprecipitation of HA-A2AR-HA and D2R from membrane preparations of mouse Ltk
 fibroblasts. Ltk fibroblasts
stably transfected with either human dopamine D2R (long form) or human dopamine D1R were transiently transfected with either double-tagged
HA-A2AR-HA (HA-A2AR-HA/D2R and HA-A2AR-HA/D1R cells) or an irrelevant plasmid (D2R and D1R cells). An aliquot of cell membrane extracts
was used as a positive control. WB, Western blot; IP, immunoprecipitation.
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but significantly reduced forskolin (10 M)-induced cAMP ac-
cumulation (Fig. 8B). Finally, CGS 21680 (1 M) counteracted
the effect of quinpirole on forskolin-induced cAMP accumula-
tion (Fig. 8B). These results provide a functional demonstration
of the antagonistic A2AR/D2R interactions in striatal neurons
in culture.
DISCUSSION
The main findings of the present work are first that A2AR
and D2R are colocalized and form heteromers in untreated
neuronal cells and that they coaggregate upon long term expo-
sure to either agonist. The formation of A2AR/D2R heteromers
and aggregates is receptor subtype-specific because co-expres-
sion of A2AR/D1R (present study) or A1R/D2R (6) does not lead
to formation of heteromers. Furthermore, A2AR did not form
heteromeric complexes with A1R (present study). This phenom-
enon may therefore constitute the molecular basis for the se-
lective A2AR/D2R interactions observed in vitro, like A2AR mod-
ulation of D2 binding characteristics (7, 8, 22, 23),
counteraction of D2R-mediated intracellular [Ca
2i] responses
(7), and inhibition of cAMP accumulation (see Ref. 23 and
present paper). The same type of antagonism was observed in
vivo with the A2AR inhibition of D2R-mediated regulation of
GABA release in the globus pallidus and of D2R-mediated
increases in motor activity (1, 5). Besides acute antagonistic
actions, the A2AR/D2R heteromers may be involved in receptor
trafficking, because long term exposure to either A2AR or D2R
agonists induces aggregation and cotreatment with these ago-
nists induces internalization of both receptors. Moreover, prior
exposure to A2AR or D2R agonists can produce a desensitization
of the A2AR in terms of cAMP accumulation associated with
coaggregation. In contrast, co-exposure to A2AR and D2R ago-
nists, but not to any of the two agonists alone, causes desensi-
tization of D2R-mediated inhibition of cAMP accumulation,
which is associated with cointernalization. The present obser-
vation that A2AR and D2R functions are simultaneously altered
after long exposure to agonists can aid in understanding be-
havioral findings involving cross-tolerance and cross-sensitiza-
tion between dopamine agonists and compounds active at aden-
osine receptors (such as caffeine) (24, 25). Together with other
recently reported findings, the present results suggest that
changes in A2AR function may be involved in the secondary
effects observed after chronic intermittent treatment with L-
DOPA such as reduced antiparkinsonian activity and dyskine-
sia (26). Adenosine is a feedback detector of neuronal activa-
tion, in view of the fact that it allows the neuronal network to
return into a resting state (27). Adenosine is therefore expected
to increase in the striatal extracellular fluid from patients with
Parkinson’s disease mainly after chronic intermittent L-DOPA
FIG. 7. Double immunofluorescence staining and confocal im-
ages of striatal neurons in culture. Panel A, cells were exposed for
6 h to either 100 nM CGS-21680, 10 M quinpirole, or both and were
processed for immunostaining using fluorescein (green)-conjugated rab-
bit anti-A2AR antibodies and rhodamine (red)-conjugated rabbit anti-
D2R antibodies. The cells were analyzed by confocal microscopy. Super-
imposition of images reveals the colocalization of A2AR and D2R in
yellow. Panel B, staining of adenosine A1R with fluorescein (green)-
conjugated anti-A1R antibodies. Note the lack of effect of 10 M quin-
pirole (6 h). Representative images from four to five independent ex-
periments/treatment are shown; scale bar, 10 m.
FIG. 8. cAMP accumulation experiments in striatal neurons in
culture. Results represent means S.E. and are expressed as percent-
age of conversion of total [3H]ATP to [3H]cAMP (n  10–14). A, effects
of 10 and 30 M forskolin (F10 and F30, respectively), 1 M CGS 21680
(CGS), and 1 M quinpirole (Q). Forskolin, but not CGS 21680, signif-
icantly increased cAMP accumulation. **, p  0.01 compared with
control (C); one-way ANOVA. B, effects of 10 M forskolin (F), 1 M CGS
21680 (CGS), and 1 M quinpirole (Q), alone or in combination. CGS
21680 counteracted the inhibitory effect of quinpirole on forskolin-
induced cAMP accumulation.  and , p  0.05 and p  0.01,
respectively, compared with forskolin; one-way ANOVA and post hoc
Scheffe’s multiple comparison test.
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treatment and in agreement with the evidence of increased
striatal glutamate drive (28). Hence, striatal extracellular lev-
els of adenosine have been found to increase in the 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s dis-
ease (29). Thus, the wearing off of the antiparkinsonian action
of L-DOPA treatment may in part be caused by the simultane-
ous chronic activation of A2AR and D2R that, according to the
present results, may lead to substantial cointernalization of
both receptors. The coadministration of A2AR antagonists to-
gether with L-DOPA or dopamine D2R agonists may therefore
provide a new therapeutic approach lacking the secondary ef-
fects of chronic L-DOPA treatment (30, 31). Overall, the present
and previous (1, 5) data implicate that the membrane interac-
tions taking place between A2AR and D2R via heteromeric
complexes represent a crucial mechanism influencing D2R-
mediated transmission. This prompts development of adeno-
sine and dopamine antagonists/agonists compounds preferen-
tially active on A2AR/D2R heteromers as new drugs for the
treatment of neuropsychiatric diseases, such as Parkinson’s
disease (30, 31), schizophrenia (32, 33), Huntington’s disease
(34), and dystonia (35), in which D2R have been implicated.
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